The importance of the telomere and telomerase system in hematological malignancies

References

• Hayffick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961;25:585–621.
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The emerging p53 gene family. J Natl Cancer Inst 1999;91:594–598.
   PubMed Web of Science ®Google Scholar
• Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256:271–282.
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Synthesis of telomeres by the ribonucleopro-tein telomerase. FASEB J 1991;5:A1784.
   Web of Science ®Google Scholar
• Kim SH, Kaminker P, Campisi J. Telomeres, aging and cancer: in search of a happy ending. Oncogene 2002;21:503–511.
   Google Scholar
• Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002;21:564–579.
   PubMed Web of Science ®Google Scholar
• Moyzis RK, Buckingham JM, Cram LS, Darn M, Deaven LL, Jones MD et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988;85:6622–6626.
   PubMed Web of Science ®Google Scholar
• de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killery AM et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518–527.
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Structure and function of telomeres. Nature 1991;350:569–573.
   PubMed Web of Science ®Google Scholar
• Greider CW. Telomeres do D-loop-T-loop. Cell 1999;97:419–422.
   PubMed Web of Science ®Google Scholar
• Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H et al. Mammalian telomeres end in a large duplex loop. Cell 1999;97:503–514.
   PubMed Web of Science ®Google Scholar
• Lippman Z, Gendrel AV, Black M, Vaughn MW, Dedhia N, McCombie WR et al. Role of transposable elements in heterochromatin and epigenetic control. Nature 2004;430:471–476.
   PubMed Web of Science ®Google Scholar
• Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 2003;22:131–146.
   PubMed Web of Science ®Google Scholar
• Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P et al. A human telomeric protein. Science 1995;270:1663–1667.
   PubMed Web of Science ®Google Scholar
• van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998;92:401–413.
   Google Scholar
• Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB et al. A mammalian telomerase-associated protein. Science 1997;275:973–977.
   PubMed Web of Science ®Google Scholar
• Lei M, Podell ER, Cech TR. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat Struct Mol Biol 2004;11: 1223–1229.
   Google Scholar
• Kuimov AN. Polypeptide components of telomere nucleo-protein complex. Biochemistry (Mose) 2004;69:117–129.
   PubMed Web of Science ®Google Scholar
• Paull TT, Gellert M. The 3' to 5' exonuclease activity of Mre 11 facilitates repair of DNA double-strand breaks. Mol Cell 1998;1:969–979.
   PubMed Web of Science ®Google Scholar
• Cerni C. Telomeres, telomerase, and myc. An update. Mutat Res 2000;462:31–47.
   PubMed Web of Science ®Google Scholar
• Wright WE, Shay JW. Telomere positional effects and the regulation of cellular senescence. Trends Genet 1992;8:193–197.
   PubMed Web of Science ®Google Scholar
• van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997;385:740–743.
   PubMed Web of Science ®Google Scholar
• Ohki R, Ishikawa F. Telomere-bound TRF1 and TRF2 stall the replication fork at telomeric repeats. Nucleic Acids Res 200432:1627-1637.
   PubMed Web of Science ®Google Scholar
• Iwano T, Tachibana M, Reth M, Shinkai Y. Importance of TRF1 for functional telomere structure. J Biol Chem 2004;279:1442–1448.
   PubMed Web of Science ®Google Scholar
• Kawanishi S, Oikawa S. Mechanism of telomere shortening by oxidative stress. Ann NY Acad Sci 2004;1019:278–284.
   PubMed Web of Science ®Google Scholar
• Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 2004;117:2417–2426.
   PubMed Web of Science ®Google Scholar
• Molenaar C, Wiesmeijer K, Verwoerd NP, Khazen S, Eils R, Tanke HJ et al. Visualizing telomere dynamics in living mammalian cells using PNA probes. EMBO J 2003;22:6631–6641.
   PubMed Web of Science ®Google Scholar
• Chuang TC, Moshir S, Garini Y, Chuang AY, Young IT Vermolen B et al. The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol 2004;2:12.
   Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–2014.
   PubMed Web of Science ®Google Scholar
• Mochizuki Y, He J, Kulkarni S, Bessler M, Mason PJ. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci USA 2004;101:10756–10761.
   Google Scholar
• Chang W, Dynek JN, Smith S. TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. Genes Dev 2003;17: 1328–1333.
   Google Scholar
• Aisner DL, Wright WE, Shay JW. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 2002;12:80–85.
   PubMed Web of Science ®Google Scholar
• Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998;12:1769–1774.
   PubMed Web of Science ®Google Scholar
• Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 2001;264:74–99.
   PubMed Web of Science ®Google Scholar
• Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A et al. Switch from Myc/Max to Madl/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA 2001;98:3826–3831.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Kyo S, Takakura M, Kanaya T, Kitagawa Y, Itoh H et al. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res 2000;28:2557–2562.
   PubMed Web of Science ®Google Scholar
• Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR The hTERT alpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000;2:426–432.
   PubMed Web of Science ®Google Scholar
• McEachern MJ, Krauskopf A, Blackburn EH. Telomeres and their control. Annu Rev Genet 2000;34:331–358.
   PubMed Web of Science ®Google Scholar
• Ray S, Karamysheva Z, Wang L, Shippen DE, Price CM. Interactions between telomerase and primase physically link the telomere and chromosome replication machinery. Mol Cell Biol 2002;22:5859–5868.
   Google Scholar
• Singh SM, Lue NF. Ever shorter telomere 1 (EST1)-dependent reverse transcription by Candida telomerase in vitro: evidence in support of an activating function. Proc Natl Acad Sci USA 2003;100:5718–5723.
   PubMed Web of Science ®Google Scholar
• Smogorzewska A, De Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem 2004;73:177–208.
   PubMed Web of Science ®Google Scholar
• Ye JZ, Hock Meyer D, Krutchinsky AN, Loayza D, Hooper SM, Chait BT et al. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/ TRF1 complex. Genes Dev 200418:1649-1654.
   PubMed Web of Science ®Google Scholar
• LaBranche H, Dupuis S, Ben-David Y, Bani MR, Wellinger RJ, Chabot B. Telomere elongation by hnRNP Al and a derivative that interacts with telomeric repeats and telomer-ase. Nat Genet 1998;19:199–202.
   Google Scholar
• Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998;282:1484–1487.
   Google Scholar
• Chan SW, Blackburn EH. New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin. Oncogene 2002;21:553–563.
   PubMedGoogle Scholar
• Zhang P, Chan SL, Fu W, Mendoza M, Mattson MP. TERT suppresses apoptosis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein-binding ability. FASEB J 2003;17: 767–769.
   Google Scholar
• Gonzalez-Suarez E, Samper E, Ramirez A, Flores JM, Martin-Caballero J, Jorcano JL et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 2001;20:2619–2630.
   PubMed Web of Science ®Google Scholar
• Gorbunova V, Seluanov A. Telomerase as a growth-promot-ing factor. Cell Cycle 2003;2:534–537.
   PubMed Web of Science ®Google Scholar
• Weinrich L, Pruzan R, Ma L, Ouellette M, Tesmet VM, Hull SE. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997;17:498–502.
   PubMed Web of Science ®Google Scholar
• Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996;18:173–179.
   Google Scholar
• Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14:4240–4248.
   Google Scholar
• Teng SC, Zakian VA. Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol Cell Biol 1999;19:8083–8093.
   PubMed Web of Science ®Google Scholar
• Teng SC, Chang J, McCowan B, Zakian VA. Telomerase-independent lengthening of yeast telomeres occurs by an abrupt Rad50p-dependent; Rif-inhibited recombinational process. Mol Cell 2000;6:947–952.
   PubMed Web of Science ®Google Scholar
• Tsai YL,, Tseng SF, Chang SH, Lin CC, Teng SC. Involvement of replicative polymerases, Tel lp, Meclp, Cdcl3p, and the Ku complex in telomere-telomere recombination. Mol Cell Biol 2002;22:5679–5687.
   PubMed Web of Science ®Google Scholar
• Londono-Vallejo JA, Der-Sarkissian H, Gazes L, Bacchetti S, Reddel RR. Alternative lengthening of telomeres is char-acterized by high rates of telomeric exchange. Cancer Res 2004;64:2324–2327.
   PubMed Web of Science ®Google Scholar
• Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control 2003;l0:9–16.
   Google Scholar
• Hao QL, Thiemann FT, Petersen D, Smogorzewska EM, Crooks GM. Extended long term culture reveals a highly quiescent and primitive human hematopoietic progenitor population. Blood 1996;88:3306–3313.
   Google Scholar
• Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994;91:9857–9860.
   PubMed Web of Science ®Google Scholar
• Lansdorp PM, Dragowska W, Thomas TE, Little MT, Mayani H. Age-related decline in proliferative potential of purified stem cell candidates. Blood Cells 1994;20:376–380.
   Google Scholar
• Van Ziffle JA, Baerlocher GM, Lansdorp PM. Telomere length in subpopulations of human hematopoietic cells. Stem Cells 2003;21:654–660.
   PubMed Web of Science ®Google Scholar
• Lansdorp PM. Telomere length and proliferation potential of hematopoietic stem cells. J Cell Sci 1995;108:1–6.
   PubMed Web of Science ®Google Scholar
• Verfaillie CM, Pera MF, Lansdorp PM. Stem cells: hype and reality. Hematology 2002;369–391.
   Google Scholar
• Rufer N, Brummendorf TH, Kolvraa S, Bischoff C, Christensen K, Wadsworth L et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999;190:157–167.
   PubMed Web of Science ®Google Scholar
• Slagboom PE, Droog S, Boomsma DI. Genetic determina-tion of telomere size in humans: a twin study of three age groups. Am J Hum Genet 1994;55:876–882.
   Google Scholar
• Akbar AN, Beverley PC, Salmon M. Opinion: will telomere erosion lead to a loss of T-cell memory? Nat Rev Immunol 2004;4:737–743.
   Google Scholar
• Edelstein-Keshet L, Israel A, Lansdorp P. Modelling perspectives on aging: can mathematics help us stay young? J Theor Biol 2001;213:509–525.
   Google Scholar
• Shepherd BE, Guttorp P, Lansdorp PM, Abkowitz JL. Estimating human hematopoietic stem cell kinetics using granulocyte telomere lengths. Exp Hematol 2004;32:1040–1050.
   PubMed Web of Science ®Google Scholar
• Elwood N. Telomere biology of human hematopoietic stem cells. Cancer Control 2004;11:77–85.
   PubMedGoogle Scholar
• Chu F, Feng K, Nan X, Yuan HF, Wang DM, Zhang R et al. Expression of telomerase during induction of committed differentiation of human cord blood hematopoietic stem/ progenitor cells in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002;10:281–284.
   PubMedGoogle Scholar
• Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 1996;14:239–248.
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Glaser S, Ketteler R, Waller CF, Kling-muller U, Martens UM. Effects of telomerase modulation in human hematopoietic progenitor cells. Stem Cells 2004;22:741–749.
   Google Scholar
• Weng NP, Hathcock KS, Hodes RJ. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity 1998;9:151–157.
   Google Scholar
• Allsopp RC, Cheshier S, Weissman IL. Telomerase activa-tion and rejuvenation of telomere length in stimulated T cells derived from serially transplanted hematopoietic stem cells. J Exp Med 2002;196:1427–1433.
   Google Scholar
• Weng NP, Levine BL, June CH, Hodes RJ. Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 1996;183:2471–2479.
   PubMed Web of Science ®Google Scholar
• Hu BT, Lee SC, Marin E, Ryan DH, Insel RA. Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol 1997;159:1068–1071.
   Google Scholar
• Weng NP, Palmer LD, Levine BL, Lane HC, June CH, Hodes RJ. Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differ-entiation, activation, and aging. Immunol Rev 1997;160:43–54.
   PubMed Web of Science ®Google Scholar
• Martens UM, Brass V, Sedlacek L, Pantic M, Exner C, Guo Yet al. Telomere maintenance in human B lymphocytes. Br J Haematol 2002;119:810–818.
   PubMed Web of Science ®Google Scholar
• Hathcock KS, Kaech SM, Ahmed R, Hodes RJ. Induction of telomerase activity and maintenance of telomere length in virus-specific effector and memory CD8 + T cells. J Immunol 2003;170:147–152.
   PubMed Web of Science ®Google Scholar
• Son NH, Murray S, Yanovski J, Hodes RJ, Weng N. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age. J Immunol 2000;165:1191–1196.
   Google Scholar
• Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood 1998;91:3582–3592.
   Google Scholar
• Lee JJ, Kook H, Chung IJ, Na JA, Park MR, Hwang TJ et al. Telomere length changes in patients with aplastic anaemia. Br J Haematol 2001;112:1025–1030.
   PubMed Web of Science ®Google Scholar
• Brummendorf TH, Rufer N, Holyoake TL, Maciejewski J, Barnett MJ, Eaves CJ et al. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann NY Acad Sci 2001;938:293–303.
   PubMed Web of Science ®Google Scholar
• Polychronopoulou S, Koutroumba P. Telomere length variation and telomerase activity expression in patients with congenital and acquired aplastic anemia. Acta Haematol 2004;111:125–131.
   PubMed Web of Science ®Google Scholar
• Shen JB, Tang JY, Zhao JC, Pan C, Chen J, Zhou X et al. Telomerase activity and its correlation with the proliferative potential of bone marrow in aplastic anemia in children. Acta Haematol 2002;107:208–212.
   PubMed Web of Science ®Google Scholar
• Vulliamy T, Marrone A, Dokal I, Mason PJ. Association between aplastic anaemia and mutations in telomerase RNA. Lancet 2002;22:2168–2170.
   Web of Science ®Google Scholar
• Dokal I, Vulliamy T. Dyskeratosis congenita: its link to telomerase and aplastic anaemia. Blood Rev 2003;17:217–225.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Iwama H, Yahata N, Ando K, Hayashi S, Shay JW et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Chin Cancer Res 1999;5:1155–1160.
   Web of Science ®Google Scholar
• Sieglova Z, Zilovcova S, Cermak J, Rihova H, Brezinova D, Dvorakova R et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Leuk Res 2004;28:1013–1021.
   PubMed Web of Science ®Google Scholar
• Baur JA, Zou Y, Shay JW, Wright WE. Telomere position effect in human cells. Science 2001;292:2075–2077.
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Iwama H, Yahata N, Tauchi T, Kawakubo K, Shimamoto T et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk Lym-phoma 2001;42:291–299.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Karube K, Shimazaki K, Kamma H, Suzumiya J, Hamasaki M et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma 2003;44:1339–1346.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW. Clinical implications of telomerase activity levels in acute leukemia. Chin Cancer Res 1997;3:619–625.
   Web of Science ®Google Scholar
• Yamada O, Oshimi K, Motoji T, Mizoguchi H. Telomeric DNA in normal and leukemic blood cells. J Clin Invest 1995;95:1117–1123.
   PubMed Web of Science ®Google Scholar
• Li B, Yang J, Andrews C, Chen YX, Toofanfard P, Huang RW et al. Telomerase activity in preleukemia and acute myelogenous leukemia. Leuk Lymphoma 2000;36:579–587.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 2000;60:610–617.
   Google Scholar
• Kubuki Y, Suzuki M, Sasaki H, Toyama T, Yamashita K, Maeda K et al. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma 2005;46:393–399.
   PubMed Web of Science ®Google Scholar
• Cogulu O, Kosova B, Karaca E, Gunduz C, Ozkinay F, Aksoylar S et al. Evaluation of telomerase mRNA (hTERT) in childhood acute leukemia. Leuk Lymphoma 2004;45:2477–2480.
   PubMed Web of Science ®Google Scholar
• Preisler HD, Li B, Yang BL, Huang RW, Devemy E, Venugopal P et al. Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4. Chin Cancer Res 2000;6:807–812.
   Web of Science ®Google Scholar
• Brummendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000;95:1883–1890.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002;21:680–687.
   PubMed Web of Science ®Google Scholar
• Bakalova R, Ohba H, Zhelev Z, Kubo T, Fujii M, Ishikawa M et al. Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells. FEBS Lett 2004;564:73–84.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Manshouri T, Cones J, Faderl S, Giles FJ et al. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer 2003;97:1248–1252.
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leuke-mia 1997;11:190–194.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 2000;96:358–361.
   PubMed Web of Science ®Google Scholar
• Brummendorf TH, Ersoz I, Hartmann U, Balabanov S, Wolke H, Paschka P et al. Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia. Ann NY Acad Sci 2003;996:26–38.
   PubMed Web of Science ®Google Scholar
• Najfeld V. FISHing among myeloproliferative disorders. Semin Hematol 1997;34:55–63.
   PubMed Web of Science ®Google Scholar
• Terasaki Y, Okumura H, Ohtake S, Nakao S. Accelerated telomere length shortening in granulocytes: a diagnostic marker for myeloproliferative diseases. Exp Hematol 2002;30:1399–1404.
   PubMed Web of Science ®Google Scholar
• Ferraris AM, Mangerini R, Pujic N, Racchi O, Rapezzi D, Gallamini A et al. High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythe-mia. Blood 2005;105:2138–2140.
   PubMed Web of Science ®Google Scholar
• Bock O, Serinsoz E, Schlue J, Kreipe H. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk Res 2004;28:457–460.
   PubMed Web of Science ®Google Scholar
• Remes K, Norrback KF, Rosenquist R, Mehle C, Lindh J, Roos G. Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse. Br J Cancer 2000;82:601–607.
   PubMed Web of Science ®Google Scholar
• Chiu KC, Fine M, Ilde D, Slovak ML, Arber DA. Telomerase activity and proliferation index in aggressive mature B-cell lymphoma: comparison to germinal center phenotypic markers. Hum Pathol 2003;34:1259–1264.
   Google Scholar
• Klapper W, Krams M, Qian W, Janssen D, Parwaresch R. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br J Cancer 2003;89:713–719.
   Google Scholar
• Norrback KF, Enblad G, Erlanson M, Sundstrom C, Roos G. Telomerase activity in Hodgkin's disease. Blood 1998;92:567–573.
   Google Scholar
• Brousset P, Chaouche N, Al Saati T, Zenou RC, Delsol G. Telomerase activity in Hodgkin's disease. Leuk Lymphoma 1998;30:189–192.
   PubMed Web of Science ®Google Scholar
• Heine B, Hummel M, Demel G, Stein H. Hodgkin and Reed- Sternberg cells of classical Hodgkin's disease over-express the telomerase RNA template (hTR). J Pathol 1999;188:139–145.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Sugihara M, Haraoka S, Suzumiya J, Kanda M, Kawasaki C et al. Possible immortalization of Hodgkin and Reed- Sternberg cells: telomerase expression, lengthening of telomere, and inhibition of apoptosis by NF-kappaB expres-sion. Leuk Lymphoma 2001;41:367–376.
   PubMed Web of Science ®Google Scholar
• Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995;85:2315–2320.
   Google Scholar
• Trentin L, Ballon G, Ometto L, Perin A, Basso U, Chieco-Bianchi L et al. Telomerase activity in chronic lymphopro-liferative disorders of B-cell lineage. Br J Haematol 1999;106:662–668.
   PubMed Web of Science ®Google Scholar
• Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res 1998;58:4918–4922.
   PubMed Web of Science ®Google Scholar
• Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, Sison C et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004;103:375–382.
   PubMed Web of Science ®Google Scholar
• Peng B, Zhang M, Sun R, Lin YC, Chong SY, Lai H et al. The correlation of telomerase and IL-10 with leukemia transformation in a mouse model of chronic lymphocytic leukemia (CLL). Leuk Res 1998;22:509–516.
   PubMed Web of Science ®Google Scholar
• Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, Moore MA. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytoge-netic status, and overall survival. Blood 2003;101:4982–4989.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002;62:3876–3882.
   PubMedGoogle Scholar
• Drucker L, Uziel O, Tohami T, Shapiro H, Radnay J, Yarkoni S et al. Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. Mol Pharmacol 2003;64:415–420.
   PubMed Web of Science ®Google Scholar
• Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H et al. Clinical significance of telomerase activity in multiple myeloma. Cancer 2002;94:2232–2238.
   PubMed Web of Science ®Google Scholar
• Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164–1170.
   PubMed Web of Science ®Google Scholar
• Boklan J, Nanjangud G, MacKenzie KI,, May C, Sadelain M, Moore MA. Limited proliferation and telomere dysfunc-tion following telomerase inhibition in immortal murine fibroblasts. Cancer Res 2002;62:2104–2114.
   Google Scholar
• Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S et al. Telomerase inhibition with an oligonucleo-tide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004;103:258–266.
   PubMed Web of Science ®Google Scholar
• Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 2002;1:657–665.
   PubMed Web of Science ®Google Scholar
• El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005;105: 1742–1749.
   Google Scholar
• Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001;20:6958–6968.
   PubMed Web of Science ®Google Scholar
• Izbicka E, Wheelhouse RT, Raymond E, Davidson KK, Lawrence RA, Sun D et al. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res 1999;59:639–644.
   PubMed Web of Science ®Google Scholar
• Grand CL, Han H, Munoz R1‘4, Weitman S, Von Hoff DD, Hurley LH et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcrip-tase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002;1: 565–573.
   Google Scholar
• Sumi M, Tauchi T, Sashida G, Nakajima A, Gotoh A, Shin-Ya K et al. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int J Oncol 2004;24:1481–1487.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC. Effects of oligonucleotide N3'- P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 2003;63:6187–6194.
   PubMed Web of Science ®Google Scholar
• Pang JX, Cheng XY, Xu W, Wu SG. Antisense Sp 1 oligodeoxynucleotide decreases telomerase activity by inhi-biting hTERT mRNA expression in Jurkat T cells. Acta Pharmacol Sin 2003;24:91–99.
   PubMed Web of Science ®Google Scholar
• Katz MH, Spivack DE, Takimoto S, Fang B, Burton DW, Moossa AR et al. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol 2003;10:762–772.
   PubMed Web of Science ®Google Scholar
• Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000;60:5359–5364.
   PubMed Web of Science ®Google Scholar
• Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 2002;9:30–37.
   PubMed Web of Science ®Google Scholar
• Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGre-gor F, Evans TR, Ganly I et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Onco-gene 2003;22:370–380.
   Web of Science ®Google Scholar
• Takeda T, Inaba H, Yamazaki M, Kyo S, Miyamoto T, Suzuki S et al. Tumor-specific gene therapy for undiffer-entiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J Chin Endocrinol Metab 2003;88:3531–3538.
   PubMed Web of Science ®Google Scholar
• Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, Streuli M et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999;146:917–928.
   PubMed Web of Science ®Google Scholar
• Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000;97:4796–4801.
   Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673–679.
   PubMed Web of Science ®Google Scholar
• Tajima K, Ito Y, Demachi A, Nishida K, Akatsuka Y, Tsujimura K et al. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. Int J Cancer 2004;110:403–412.
   PubMed Web of Science ®Google Scholar
• Tim LV, Loveday RL, Madden LA, Cawkwell L, Monson JR, Greenman J. Cytotoxic T-cell immunity against telomer-ase reverse transcriptase in colorectal cancer patients. Oncol Rep 2004;12:871–876.
   PubMed Web of Science ®Google Scholar
• Verra NC, Jorritsma A, Weijer K, Ruizendaal JJ, Voordouw A, Weder P et al. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res 2004;64:2153–2161.
   PubMed Web of Science ®Google Scholar
• Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000;59:1489–1499.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL-positive cells. Nat Med 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Chin Cancer Res 2002;8:3341–3347.
   Web of Science ®Google Scholar
• Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 2002;61:1154–1162.
   Google Scholar
• Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, von Zglinicki T. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 2001;61:3053–3061.
   Google Scholar
• Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 1998;16:2243–2248.
   PubMed Web of Science ®Google Scholar
• Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003;63:579–585.
   Google Scholar
• Brown T, Sigurdson E, Rogatko A, Broccoli D. Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol 2003;10:910–915.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao EH, Liang XQ, Qin JF. Increasing sensitivity to arsenic trioxide- induced apoptosis by altered telomere state. Eur J Pharmacol 2003;474:141–147.
   PubMed Web of Science ®Google Scholar
• Chen Z, Koeneman KS, Corey DR Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 2003;63:5917–5925.
   PubMed Web of Science ®Google Scholar
• Tauchi T, Shin-Ya K, Sashida G, Sumi M, Nakajima A, Shimamoto T. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against hu-man leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 2003;22:5338–5347.
   PubMed Web of Science ®Google Scholar
• Maida Y, Kyo S, Kanaya T, Wang Z, Yatabe N, Tanaka Met al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 2002;21:4071–4079.
   Google Scholar
• Bakalova R, Ohba H, Zhelev Z, Ishikawa M, Shinohara Y, Baba Y. Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase - a potential reason for resistance to Glivec in chronic myelogenous leukaemia. Biochem Phar-macol 2003;66:1879–1884.
   PubMed Web of Science ®Google Scholar
• Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L et al. Telomere dysfunction alters the chemother-apeutic profile of transformed cells. Proc Natl Acad Sci USA 2001;98:3381–3386.
   PubMed Web of Science ®Google Scholar
• Tchirkov A, Lansdorp PM. Role of oxidative stress in telomere shortening in cultured fibroblasts from normal individuals and patients with ataxia- telangiectasia. Hum Mol Genet 2003;12:227–232.
   PubMed Web of Science ®Google Scholar
• D'Amours D, Jackson SP. The Mre 1 1 complex: at the crossroads of DNA repair and checkpoint signaling. Nat Rev Mol Cell Biol 2002;3:317–327.
   PubMed Web of Science ®Google Scholar
• Bouchal J, Baumforth KR, Svachova M, Murray PG, von Angerer E, Kolar Z. Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol 2005;57:83–92.
   PubMed Web of Science ®Google Scholar
• Rubio MA, Davalos AR, Campisi J. Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress. Exp Cell Res 2004;298:17–27.
   Google Scholar
• Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M, Biroccio A, Gold B, Lombardi ML, Graziani G. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. Mol Pharmacol 2003;63:192–202.
   PubMed Web of Science ®Google Scholar
• Fu W, Begley JG, Killen MW, Mattson MP. Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 1999;274:7264–7271.
   PubMed Web of Science ®Google Scholar
• Inches CM, Schultes CM, Kelland LR, Neidle S. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor. Mol Pharmacol 2003;64:1101–1108.
   Google Scholar
• Lyu SY, Choi SH, Park WB. Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled path-way independent of p53. Arch Pharm Res 2002;25: 93–101.
   Google Scholar
• Chen Z, Koeneman KS, Corey DR. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 2003;63:5917–5925.
   PubMed Web of Science ®Google Scholar
• Biroccio A, Gabellini C, Amodei S, Benassi B, Del Bufalo D, Elli R, Antonelli A, D'Incalci M, Zupi G. Telomere dysfunction increases cisplatin and ecteinascidin-743 sensi-tivity of melanoma cells. Mol Pharmacol 2003;63: 632–638.
   Google Scholar
• Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 1998;351:178–181.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Hoshi Y, Sakurai S, Yamada H, Yamada O, Mizoguchi H. Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant 1998;21:167–171.
   PubMed Web of Science ®Google Scholar
• Lee J, Kook H, Chung I, Kim H, Park M, Kim C et al. Telomere length changes in patients undergoing hemato-poietic stem cell transplantation. Bone Marrow Transplant 1999;24:411–415.
   PubMed Web of Science ®Google Scholar
• Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921–1929.
   PubMed Web of Science ®Google Scholar
• Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al. Solid cancers after bone marrow transplanta-tion. N Engl J Med 1997;336:897–905.
   PubMed Web of Science ®Google Scholar
• Awaya N, Baerlocher GM, Manley TJ, Sanders JE, Mielcarek M, Torok-Storb B et al. Telomere shortening in hematopoietic stem cell transplantation: a potential mechan-ism for late graft failure? Biol Blood Marrow Transplant 2002;8:597–600.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Asai O, Kuraishi Y, Urashima M, Hoshi Y, Sakamaki H et al. Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2000;25:441–447.
   Google Scholar
• Robertson JD, Testa NG, Russell NH, Jackson G, Parker AN, Milligan DW et al. Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant 2001;27:1283–1286.
   PubMed Web of Science ®Google Scholar
• de Pauw ES, Otto SA, Wijnen JT, Vossen JM, van Weel MH, Tanke HJ et al. Long-term follow-up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haemato-poietic stem cell exhaustion. Br J Haematol 2002;116:491–496.
   PubMed Web of Science ®Google Scholar
• Thornley I, Sutherland R, Wynn R, Nayar R, Sung L, Corpus G et al. Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood 2002;99:2387–2396.
   PubMed Web of Science ®Google Scholar
• Rufer N, Brummendorf TH, Chapuis B, Helg C, Lansdorp PM, Roosnek E. Accelerated telomere shortening in hema-tological lineages is limited to the first year following stem cell transplantation. Blood 2001;97:575–577.
   PubMed Web of Science ®Google Scholar
• Lahav M, Nagler A, Shapiro H, Uziel O. Non myeloablative conditioning does not prevent telomere attrition after stem cell transplantation. ASH Meeting, 2002;800.
   Google Scholar
• Lincz LF, Scorgie FE, Sakoff JA, Fagan KA, Ackland SP, Enno A. Telomere length predicts neutrophil recovery in the absence of G-CSF after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2004;34:439–445.
   PubMed Web of Science ®Google Scholar
• Szyper-Kravitz M, Uziel O, Shapiro H, Radnay J, Katz T, Rowe JM et al. Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34 + haematopoietic cells and may prevent telomere attrition after chemotherapy. Br J Haematol 2003;120:329–336.
   PubMed Web of Science ®Google Scholar
• Thornley I, Freedman MH. Telomeres, X-inactivation ratios, and hematopoietic stem cell transplantation in hu-mans: a review. Stem Cells 2002;20:198–204.
   PubMed Web of Science ®Google Scholar
• Allsopp RC, Weissman IL. Replicative senescence of hematopoietic stem cells during serial transplantation: does telomere shortening play a role?. Oncogene 2002;21:3270–3273.
   PubMed Web of Science ®Google Scholar
• Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplanta-tion. Blood 2003;102:517–520.
   Google Scholar